JAK3 Inhibitor (Rigel)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameJAK3 Inhibitor (Rigel)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK3 inhibitors
TargetsTyrosine-protein kinase JAK3
Therapy Area/IndicationsLupus Erythematosus, Discoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRigel Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRigel Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsLupus Erythematosus, Discoid

Other Information

ATC CodeN/A
Related LinksN/A